Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Abeona Therapeutics's share price for the quarter that ended in Mar. 2026 was $4.44. Abeona Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 56.87 Mil. Therefore, Abeona Therapeutics's market cap for the quarter that ended in Mar. 2026 was $252.49 Mil.
Abeona Therapeutics's quarterly market cap
increased
from Sep. 2025 ($272.42 Mil) to Dec. 2025 ($294.76 Mil) but then
declined
from Dec. 2025 ($294.76 Mil) to Mar. 2026 ($252.49 Mil).
Abeona Therapeutics's annual market cap
increased
from Dec. 2023 ($134.61 Mil) to Dec. 2024 ($255.15 Mil) and
increased
from Dec. 2024 ($255.15 Mil) to Dec. 2025 ($294.76 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Abeona Therapeutics's Enterprise Value for Today is $267.55 Mil.
Abeona Therapeutics (LTS:0H7R) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Abeona Therapeutics Market Cap Related Terms
Abeona Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Abeona Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0H7R vs RCKT, UPB, PALI: Market Cap Comparison
For the Biotechnology subindustry, Abeona Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Abeona Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (LTS:0H7R) has a Market Cap of $412.65 Mil as of Aug. 10, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Abeona Therapeutics and its competitors. According to the industry distribution chart, Abeona Therapeutics ranks #454 out of 1419 companies in the Biotechnology industry, placing it in the top 32%.
Is Abeona Therapeutics' Market Cap too high?
Abeona Therapeutics' current Market Cap is $412.65 Mil. The Biotechnology industry median Market Cap is 116.54. Abeona Therapeutics' value of $412.65 Mil is 254.1% above this industry median. Based on the distribution chart, Abeona Therapeutics ranks #454 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abeona Therapeutics has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' Market Cap compare to RCKT and UPB?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #454 out of 1419 companies for Market Cap. This puts Abeona Therapeutics in the upper half of its industry. The industry median Market Cap is 116.54. Abeona Therapeutics' value of $412.65 Mil is 254.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.54, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abeona Therapeutics's current Market Cap of $412.65 Mil is 254.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Abeona Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 116.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abeona Therapeutics's current Market Cap is $412.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Abeona Therapeutics (LTS:0H7R) is currently considered Possible Value Trap. The stock's GF Value™ is $19.19, compared to a current price of $7.17 — trading 62.6% below its estimated fair value. The current Market Cap is $412.65 Mil and 254.1% above the Biotechnology industry median of 116.54. Abeona Therapeutics' overall GF Score™ is 45/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Abeona Therapeutics (LTS:0H7R), the current Market Cap is $412.65 Mil as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abeona Therapeutics (LTS:0H7R) Overvalued in 2026?
Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued.
The current stock price of $7.17 is trading 62.6% below its estimated GF Value™ of $19.19.
GuruFocus considers Abeona Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0H7R:
Market Cap: $412.65 Mil
GF Value™: $19.19 vs. price of $7.17 (62.6% below fair value)
Industry Position: 254.1% above the Biotechnology median (#454 of 1419)
No single metric tells the full story. See the LTS:0H7R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
45GF Score
Get the complete analysis for LTS:0H7R
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H7R has been successfully added to your 
